Thermo Fisher Scientific (TMO) income statement
NYSE · Healthcare · Medical - Diagnostics & Research · 125,000 employees · CEO Marc N. Casper
- Price
- $697.00 -1.72%
- Market cap
- $258B
- Enterprise value
- $294B
- Last report
- Q3 '26 filed 2026-10-30
- Next report
- 2027-02-04 EPS est. $7.13
Thermo Fisher Scientific (TMO) reported revenue of $12.1B for Q3 '26 (+9.1% year on year), operating income of $2.26B (18.6% of revenue) and net income of $1.72B. Over the last four quarters revenue was $47.4B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.9B | $10.3B | $10.5B | $10.6B | $11.4B | $10.4B | $10.9B | $11.1B | $12.2B | $11B | $12B | $12.1B | |
| Cost of revenue | $6.93B | $6.13B | $6.2B | $6.26B | $6.93B | $6.12B | $6.45B | $6.54B | $7.2B | $6.53B | $7.05B | $6.95B | |
| Gross profit | $3.95B | $4.22B | $4.34B | $4.34B | $4.47B | $4.25B | $4.41B | $4.58B | $5.01B | $4.48B | $4.94B | $5.19B | |
| Research & development | $327M | $331M | $339M | $346M | $374M | $342M | $352M | $347M | $357M | $336M | $364M | $348M | |
| General & administrative | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.91B | $1.86B | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $479M | $583M | $718M | |
| Operating expenses | $1.96B | $2.5B | $2.59B | $2.43B | $2.2B | $2.42B | $2.49B | $2.51B | $2.71B | $2.61B | $2.86B | $2.93B | |
| Operating income | $1.99B | $1.72B | $1.76B | $1.92B | $2.27B | $1.84B | $1.92B | $2.08B | $2.3B | $1.86B | $2.09B | $2.26B | |
| Interest income | $309M | $279M | $295M | $277M | $227M | $203M | $297M | $234M | $258M | $233M | $207M | $252M | |
| Interest expense | $444M | $363M | $421M | $424M | $384M | $303M | $404M | $347M | $365M | $354M | $401M | $417M | |
| Other non-operating income (gains on investments, FX ...) | -$193M | -$231M | -$429M | -$250M | -$58M | -$83M | -$196M | -$98M | -$186M | -$9M | $0 | -$242M | |
| Total non-operating income | -$252M | -$108M | -$77M | -$188M | -$294M | -$234M | -$206M | -$247M | -$179M | -$129M | -$163M | -$175M | |
| Income before tax | $1.74B | $1.61B | $1.68B | $1.73B | $1.97B | $1.61B | $1.71B | $1.83B | $2.12B | $1.73B | $1.92B | $2.09B | |
| Income tax | $133M | $281M | $128M | $99M | $150M | $95M | $92M | $207M | $153M | $70M | $167M | $352M | |
| Net income | $1.63B | $1.33B | $1.55B | $1.63B | $1.83B | $1.51B | $1.62B | $1.62B | $1.98B | $1.65B | $1.74B | $1.72B | |
| EPS (basic) | $4.21 | $3.48 | $4.05 | $4.27 | $4.79 | $3.99 | $4.28 | $4.28 | $5.22 | $4.44 | $4.68 | $4.65 | |
| EPS (diluted) | $4.20 | $3.46 | $4.04 | $4.24 | $4.78 | $3.98 | $4.28 | $4.27 | $5.21 | $4.43 | $4.68 | $4.64 | |
| Shares (basic, weighted) | 387M | 382M | 382M | 382M | 383M | 378M | 378M | 378M | 376M | 372M | 371M | 370M | |
| Shares (diluted, weighted) | 388M | 384M | 383M | 384M | 383M | 379M | 378M | 378M | 377M | 373M | 371M | 371M | |
| Depreciation & amortization | $839M | $836M | $790M | $740M | $742M | $705M | $685M | $661M | $728M | $736M | $817M | $0 | |
| EBITDA | $3.02B | $2.79B | $2.98B | $2.91B | $3.07B | $2.63B | $2.8B | $2.83B | $3.22B | $2.62B | $2.9B | $2.51B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18.3B | $20.9B | $24.4B | $25.5B | $32.2B | $39.2B | $44.9B | $42.9B | $42.9B | $44.6B | |
| Cost of revenue | $9.69B | $11.2B | $13.4B | $14.2B | $16.2B | $19.6B | $25.9B | $25.7B | $25.2B | $26.3B | |
| Gross profit | $8.58B | $9.68B | $11B | $11.3B | $16B | $19.6B | $19B | $17.2B | $17.7B | $18.2B | |
| Research & development | $755M | $888M | $967M | $1B | $1.18B | $1.41B | $1.47B | $1.34B | $1.39B | $1.4B | |
| Other operating expenses | $96.2M | $110M | $121M | $20M | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating expenses | $5.72B | $6.41B | $7.12B | $7.09B | $8.13B | $9.32B | $10.5B | $9.75B | $10.1B | $10.1B | |
| Operating income | $2.86B | $3.27B | $3.87B | $4.26B | $7.9B | $10.3B | $8.53B | $7.45B | $7.66B | $8.11B | |
| Interest income | $48.4M | $81M | $137M | $224M | $65M | $43M | $272M | $879M | $1.08B | $993M | |
| Interest expense | $470M | $592M | $667M | $676M | $553M | $536M | $726M | $1.49B | $1.65B | $1.42B | |
| Other non-operating income (gains on investments, FX ...) | $365M | $246M | -$57M | -$487M | $114M | $941M | -$36M | -$343M | -$1.03B | -$577M | |
| Total non-operating income | -$835M | -$838M | -$610M | -$189M | -$670M | -$1.48B | -$862M | -$1.21B | -$667M | -$842M | |
| Income before tax | $2.02B | $2.43B | $3.26B | $4.07B | $7.23B | $8.84B | $7.66B | $6.24B | $7B | $7.27B | |
| Income tax | -$1.4M | $201M | $324M | $374M | $850M | $1.11B | $703M | $284M | $657M | $547M | |
| Net income | $2.02B | $2.23B | $2.94B | $3.7B | $6.38B | $7.73B | $6.95B | $6B | $6.34B | $6.74B | |
| EPS (basic) | $5.12 | $5.64 | $7.31 | $9.24 | $16.10 | $19.61 | $17.73 | $15.53 | $16.58 | $17.77 | |
| EPS (diluted) | $5.09 | $5.59 | $7.24 | $9.17 | $15.98 | $19.46 | $17.64 | $15.45 | $16.53 | $17.74 | |
| Shares (basic, weighted) | 395M | 395M | 402M | 400M | 396M | 394M | 392M | 386M | 382M | 376M | |
| Shares (diluted, weighted) | 397M | 398M | 406M | 403M | 399M | 397M | 394M | 388M | 383M | 377M | |
| Depreciation & amortization | $1.76B | $2.03B | $2.27B | $2.28B | $2.33B | $2.59B | $3.38B | $3.41B | $3.11B | $2.78B | |
| EBITDA | $4.25B | $5.05B | $6.2B | $7.02B | $10.1B | $12B | $11.9B | $11.2B | $11.8B | $11.5B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-26, 10-Q 2026-06-27, 10-Q 2026-03-28, 10-K 2025-12-31, 10-Q 2025-09-27, 10-Q 2025-06-28, 10-Q 2025-03-29, 10-K 2024-12-31, 10-Q 2024-09-28
Data as of 2026-11-01